Skip to main content

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Recruiting · Phase 1, Phase 2 · NCT06753331

Conditions: Parkinson's Disease

At a glance

Research payments reported, 2025
$424,204
U.S. investigators named
4
Sites paid
8
Planned or actual enrollment
25

About the trial

Sponsor
Sumitomo Pharma America, Inc.
Tested
DSP-1083 implantation (combination_product), Sham surgery treatment (procedure)
Dates
Started 2024-12-18; completion 2030-12-15
Results posted
Not yet

The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States

From ClinicalTrials.gov, last updated 2026-10-21. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sumitomo Pharma America, Inc. reported $424,204 in research payments for this study in 2025 (88 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Trustees of Columbia University in The City of New York $186,156
  • University of Kentucky Research Foundation $183,018
  • The Regents of the University of California $50,705
  • $1,750
  • University of California San Diego Medical Center $820
  • Columbia University Medical Center Neurological Institute $820
  • University of Kentucky Department of Neurology $770
  • University of California Davis Health System $95
  • University of Kentucky Hospital, KY $70

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.